SG11201900665VA - Cannabis composition - Google Patents

Cannabis composition

Info

Publication number
SG11201900665VA
SG11201900665VA SG11201900665VA SG11201900665VA SG11201900665VA SG 11201900665V A SG11201900665V A SG 11201900665VA SG 11201900665V A SG11201900665V A SG 11201900665VA SG 11201900665V A SG11201900665V A SG 11201900665VA SG 11201900665V A SG11201900665V A SG 11201900665VA
Authority
SG
Singapore
Prior art keywords
international
bay
western australia
perth
pct
Prior art date
Application number
SG11201900665VA
Inventor
Harry Karelis
Mara Gordon
Stewart Smith
Stewart Washer
Original Assignee
Zelda Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61072172&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201900665V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zelda Therapeutics Operations Pty Ltd filed Critical Zelda Therapeutics Operations Pty Ltd
Publication of SG11201900665VA publication Critical patent/SG11201900665VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

WO 18/0 23 163 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 February 2018 (08.02.2018) WIP0 I PCT omit VIII °nolo III mill VIII omioliono oimIE (10) International Publication Number WO 2018/023163 Al (51) International Patent Classification: A61K 31/352 (2006.01) A61K 36/00 (2006.01) A61K 31/05 (2006.01) A61P 25/20 (2006.01) (21) International Application Number: PCT/AU2017/050814 (22) International Filing Date: 03 August 2017 (03.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/370,304 03 August 2016 (03.08.2016) US (71) Applicant: ZELDA THERAPEUTICS OPERATIONS PTY LTD [AU/AU]; Level 6, 105 St Georges Terrace, Perth, Western Australia 6000 (AU). (72) Inventors: KARELIS, Harry; Level 6, 105 St Georges Terrace, Perth, Western Australia 6000 (AU). GORDON, Mara; 3901 Bay Hill Rd, Bodega Bay, California 94923 (US). SMITH, Stewart; 3901 Bay Hill Rd, Bodega Bay, California 94923 (US). WASHER, Stewart; 6 Pemberton Close, Stirling, Western Australia 6021 (AU). Published: — with international search report (Art. 21(3)) (74) Agent: GRIFFITH HACK; Level 22, Allendale Square, 77 St Georges Terrace, Perth, Western Australia 6000 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: CANNABIS COMPOSITION (57) : The present invention relates to a method for treating a sleep disorder. Preferably, the invention relates to a method for treating a sleep disorder comprising the step of administering a pharmaceutical composition comprising a Cannabis extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the Cannabis extract comprising a terpene fraction comprising limonene in an amount of at least about 5.4% by weight of the terpene fraction.
SG11201900665VA 2016-08-03 2017-08-03 Cannabis composition SG11201900665VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662370304P 2016-08-03 2016-08-03
PCT/AU2017/050814 WO2018023163A1 (en) 2016-08-03 2017-08-03 Cannabis composition

Publications (1)

Publication Number Publication Date
SG11201900665VA true SG11201900665VA (en) 2019-02-27

Family

ID=61072172

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900665VA SG11201900665VA (en) 2016-08-03 2017-08-03 Cannabis composition

Country Status (15)

Country Link
US (2) US11779562B2 (en)
EP (1) EP3493798A4 (en)
JP (1) JP2019523283A (en)
KR (2) KR20210013645A (en)
CN (1) CN109843287A (en)
AU (4) AU2017307643B2 (en)
BR (1) BR112019001852A2 (en)
CA (1) CA3031810A1 (en)
CL (1) CL2019000270A1 (en)
CO (1) CO2019001044A2 (en)
IL (2) IL296008A (en)
MX (1) MX2019001285A (en)
PE (1) PE20200726A1 (en)
SG (1) SG11201900665VA (en)
WO (1) WO2018023163A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102447510B1 (en) 2016-08-03 2022-09-27 젤리라 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 Cannabis composition
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
MX2019011510A (en) * 2017-03-30 2020-01-09 Ojai Energetics Pbc Methods and compositions for enhancing health.
US20210145910A1 (en) * 2017-06-19 2021-05-20 Zelda Therapeutics Operations Pty Ltd Sleep disorder compositions and treatments thereof
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
WO2019173242A1 (en) * 2018-03-04 2019-09-12 Cmg Partners, Inc. Enhanced smokable cannabis-based therapeutic product for treatment of sleep disorders and chronic pain and method for making same
WO2019241804A1 (en) * 2018-06-15 2019-12-19 California Cannabinoids Compositions and methods for treatment of narcolepsy and related disorders
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US20220160648A1 (en) * 2019-02-13 2022-05-26 Inspired Health Products, LLC Composition Comprising Hydrolyzed Collagen and Cannabidiol and Use Thereof
US11554098B2 (en) 2019-05-03 2023-01-17 HFL Partners, LLC Compositions comprising molecularly separated cannabinoids and terpene blends and methods of producing
US20230000935A1 (en) * 2021-07-03 2023-01-05 Joseph Anthony Bidwell Extract Infused Cannabis Flower, Natural preservation of Cannabis Flower and the method therefor

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2400319B (en) 2001-05-04 2005-06-08 Gw Pharma Ltd Cannabinoid-rich extracts
JP4411117B2 (en) * 2004-03-25 2010-02-10 エスエス製薬株式会社 Sleep improvement pharmaceutical composition
GB2418612A (en) 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
JP2007246428A (en) * 2006-03-15 2007-09-27 Nature Technology Inc Percutaneous absorption type antihypnotic composition containing plant essential oil component as active ingredient, percutaneous absorption type antihypnotic pharmaceutical formulation and method for producing the composition and formulation
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (en) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
KR20110120153A (en) * 2010-04-28 2011-11-03 고려대학교 산학협력단 Adenosine a2a receptor agonist comprising limonene
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496688B (en) 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
JP2015515977A (en) 2012-05-03 2015-06-04 エコ・ファーマシューティカルズ・ビー．ブイ．Ｅｃｈｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． Cannabis isolates containing Δ9-tetrahydrocannabinol and methods for producing such isolates
US20150313868A1 (en) * 2012-12-18 2015-11-05 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
US10792318B2 (en) 2013-03-14 2020-10-06 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
MX2015013202A (en) * 2013-03-15 2016-04-07 Biotech Inst Llc Breeding, production, processing and use of specialty cannabis.
US10265292B2 (en) 2013-09-18 2019-04-23 The Werc Shop, LLC Terpene-based compositions, processes methodologies
CA3013907C (en) * 2013-10-29 2020-09-08 Biotech Institute, Llc Production and use of specialty cannabis with bd/bt genotype and a limonene-dominant terpene profile
RU2016129536A (en) 2013-10-31 2018-01-31 Фулл Спектрум Лабораториз, Лтд. Terpen and cannabinoid preparations
WO2015200049A1 (en) * 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
CA2953684C (en) 2014-06-27 2023-01-03 Kenton L. Crowley Buccal and sublingual cannabinoid formulations and method of making the same
US11793769B2 (en) * 2014-08-25 2023-10-24 Jai Shankar Sukul Device with compositions for delivery to the lungs, the oral mucosa and the brain
JP2017535539A (en) * 2014-10-21 2017-11-30 ユナイテッド カナビス コーポレイション Cannabis extract and its preparation and use
IL252881B (en) 2014-12-12 2022-06-01 Ojai Energetics Pbc Microencapsulated cannabinoid compositions
US10406186B2 (en) 2015-01-31 2019-09-10 Constance Therapeutics, Inc. Cannabis oil extracts and compositions
MX2017010872A (en) 2015-02-27 2018-05-07 Ebbu Llc Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral.
PE20200676A1 (en) 2016-08-03 2020-06-11 Zelda Therapeutics Operations Pty Ltd CANNABIS COMPOSITION
KR102447510B1 (en) 2016-08-03 2022-09-27 젤리라 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 Cannabis composition

Also Published As

Publication number Publication date
AU2021240297B2 (en) 2023-08-24
US20220347155A1 (en) 2022-11-03
US11779562B2 (en) 2023-10-10
AU2019253841A1 (en) 2019-11-14
AU2018100923B4 (en) 2018-09-27
IL296008A (en) 2022-10-01
AU2017307643A1 (en) 2018-07-05
CL2019000270A1 (en) 2019-10-04
EP3493798A4 (en) 2020-05-06
CO2019001044A2 (en) 2019-04-30
CN109843287A (en) 2019-06-04
AU2021240297A1 (en) 2021-10-28
WO2018023163A1 (en) 2018-02-08
MX2019001285A (en) 2019-06-13
CA3031810A1 (en) 2018-02-08
AU2019253841B2 (en) 2021-07-01
JP2019523283A (en) 2019-08-22
PE20200726A1 (en) 2020-07-21
BR112019001852A2 (en) 2019-05-07
AU2017307643B2 (en) 2019-07-25
KR20210013645A (en) 2021-02-04
EP3493798A1 (en) 2019-06-12
US20230414559A1 (en) 2023-12-28
IL264461A (en) 2019-02-28
AU2018100923C4 (en) 2019-10-31
AU2018100923A4 (en) 2018-08-09
KR20190035791A (en) 2019-04-03

Similar Documents

Publication Publication Date Title
SG11201900596XA (en) Cannabis composition
SG11201900665VA (en) Cannabis composition
SG11201900501RA (en) Cannabis composition
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201907427YA (en) Engineered transferrin receptor binding polypeptides
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201906885TA (en) Methods for the administration of certain vmat2 inhibitors
SG11201804211YA (en) Compositions comprising bacterial strains
SG11201804368QA (en) Storage assembly for prosthetic valve
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201907435PA (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201908092RA (en) Anti-tigit antigen-binding proteins and methods of use thereof
SG11201909561RA (en) Octree-based convolutional neural network
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201902949PA (en) Pharmaceutical compositions and methods of treating cardiovascular diseases
SG11201804589TA (en) Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201807549TA (en) Combination of a cxcr4 antagonist and an immune checkpoint inhibitor
SG11201809882XA (en) Pharmaceutical combinations for treating cancer